First Trust Advisors
ALLO icon

First Trust Advisors’s Allogene Therapeutics ALLO Stock Holding History

First Trust Advisors’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-24,595
Closed -$266K – 2416
2022
Q3 		$266K Buy
+24,595
New +$334K ﹤0.01% 2351
2019
Q2 		– Sell
-101,816
Closed -$2.94M – 2417
2019
Q1 		$2.94M Buy
101,816
+375
+0.4% +$10.9K 0.01% 1340
2018
Q4 		$2.73M Buy
+101,441
New +$2.7M 0.01% 1292

Other funds holding ALLO

TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

First Trust Advisors's ALLO Position: Q4 2022 in Review

First Trust Advisors sold out of Allogene Therapeutics (ALLO) in Q4 2022, closing a stake of 24,595 shares — an estimated $266K sold.

First Trust Advisors first reported a position in ALLO in Q4 2018 and held it in 3 quarters. The position peaked at $2.94M in Q1 2019. 168 funds tracked by Wall St. Rank hold ALLO as of Q4 2022.

  • First Trust Advisors reported no remaining Allogene Therapeutics position as of Q4 2022 after selling out during the quarter.
  • First Trust Advisors sold 24,595 Allogene Therapeutics shares in Q4 2022, an estimated $266K.
  • First Trust Advisors first reported a position in Allogene Therapeutics in Q4 2018 and held it in 3 quarters.
  • First Trust Advisors's Allogene Therapeutics position peaked at $2.94M in Q1 2019.
  • 168 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q4 2022.

Based on First Trust Advisors's 13F filing for Q4 2022, filed 9 Feb 2023.